Summary Characteristics of cells that are associated with the hormonal dependence of tumours are described, and it is shown that clonogenicity and hormone-induced proliferative response of breast tumours are as good markers of hormonal dependence as is oestrogen receptor. Thus tumours that formed less than 150 colonies per 500,000 cells seeded and that increased their proliferative activity 1.8-fold or more in response to hormones were the tumours that were likely to respond to endocrine treatments, whereas all other tumours were likely to be refractory to endocrine treatments. These two criteria (clonogenicity and proliferative response to growth hormones) correctly identified the response to subsequent endocrine treatments in 15 out of 17 patients with oestrogen receptor-unknown tumours. It is proposed that they may constitute a substitute for the oestrogen receptor status in patients with non-biopsiable tumours, and an additional discriminant where the oestrogen receptor assay is available.
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Thirty per cent of breast tumours are hormone-dependent and can-be managed effectively with endocrine manipulations (Stoll, 1981) , but the degree of hormonal dependence varies among tumours-and changes within tumours as the disease evolves. A measurement of hormonal dependence is therefore necessary for the proper management of patients with breast carcinoma; a requirement that is the more pressing since tamoxifen has become the recommended adjuvant treatment for post-menopausal women with oestrogen receptor-positive and oestrogen receptor-unknown stage II disease (Cancer Conference, 1985) , and more recently also for similar patients with stage I disease (DeVita, 1988) . The oestrogen receptor (ER) assay identifies with a high degree of accuracy patients that will not benefit from endocrine treatment (Desombre, 1975; Wang et al., 1984) . However, its predictive value when positive is only 50%, i.e. inadequate to select for the type of curative treatment modality (endocrine versus cytotoxic). Furthermore, smaller tumours will be diagnosed as a consequence of screening procedures, and adequate tissue for the ER-assay may often no longer be available. Hence, the proportion of 'ER-unknown' tumours will increase, and the 'efficacy' of endocrine treatments will accordingly decrease. The need has therefore emerged to improve our ability to predict response to endocrine treatments with additional or more accurate tests that can also be obtained with lesser tumour tissue.
We have previously observed that the in vitro responsiveness of tumours to growth-stimulatory hormones could provide an estimate for the in vivo responsiveness of tumours to growth-inhibitory hormones: a high proliferative response of tumours to a combination of steroid and peptide hormones provided a measure that supplemented a positive ER assay by identifying patients that responded to endocrine treatment among those with ER-positive tumours (Hug et al., 1983) .
The purpose of the present report is to describe criteria that may substitute for the ER assay in patients with nonbiopsiable tumours, e.g. patients with ER-unknown tumours.
Materials and methods

Patients
The tumours of 122 patients with stage IV breast carcinoma were assayed. Of these, 15 (Clark & Peck, 1975) . Tumours that contained above 3fmol oestrogen receptor-protein per mg cytosol protein were considered ER-positive.
Clonogenicity of tumours A colony-forming assay in agar cultures was used (Hamburger & Salmon, 1977 A cut-off of 0.03% is proposed for clonogenicity and of > 1.8 for hormonal sensitivity (HPR). of 1.0% Worthington type III collagenase (Worthington Biochemical Corporation, Freehold, NJ) and 0.005% deoxyribonuclease (Sigma Chemical Co., St Louis, MO) in F12 at 37°C for 20h, under continuous agitation. Elastase, at a concentration of 0.6%, was also used to disaggregate solid tumours. Cells were washed in calcium-and magnesium-free Hank's balanced salt solution (GIBCO, Grand Island, NY) and resuspended in F 12 supplemented with 10% foetal bovine serum (FBS, KC Biological, Lenexa, KS). Remaining cell aggregates were removed by passing suspensions sequentially through 18-, 22-and 25-gauge needles. Cells were then counted with a haemocytometer and set into agar cultures.
Underlayers of cultures consisted of I ml volumes of a mixture of 70% F12, 20% conditioned medium and 10% horse serum (KC Biological, Lenexa, KS), in 0.5% agar (Bactoager Difco, American Scientific Products). Upper layers consisted of 1 ml volumes of a mixture of minimal essential medium (GIBCO, Grand Island, NY) and 15% FBS, in 0.3% agar. Conditioned medium was obtained from the supernatants of three breast tumour cell lines (Hug et al., 1984 (Lippman & Bolan, 1975; Holley, 1975; Gross et al., 1984) . Nine tumours were also assayed for the responsiveness to 17-beta-oestradiol alone. Hormones were added to both culture layers as follows: 17-betaoestradiol, 5 x 10-7M; epidermal growth factor, 50ng ml -1; insulin, 10 pgml-1; and hydrocortisone, 2.5 pgml-1. At these concentrations, hormones had maximally stimulated the growth of four breast tumour cell lines that were cultured under identical conditions (Hug et al., 1984 1 7-Beta-oestradiol, hydrocortisone, epidermal growth factor and insulin increased the proliferative activity of 96% of all tumours tested. The relative effects of 17-betaoestradiol alone and those of the combined hormones are illustrated in Figure 1 . In this group of nine tumours, a substantial increase in colony-formation occurred with the exposure to 17-beta-oestradiol in all instances; the remaining hormones medited a further increase.
We observed an inverse relationship between clonogenicity of tumours and proliferative response to hormones. As clonogenicity of tumours increased, the proliferative response to hormones decreased (difference not significant).
Although ER-positive tumours tended to be more responsive to the combined hormones (Figure 2) The relationships of clonogenicity and proliferative response to hormones were analysed as a function of the ERstatus of tumours. The findings are illustrated in Figure 3 . The observed differences in intrinsic hormonal dependence of tumours with different oestrogen-receptor status were best appreciated in the respective hormone-induced proliferative response versus clonogenicity curves, fitting the ratios of the number of colonies formed with hormones versus control against controls (Figure 3 caption) . The regression line for ER-positive tumours had a steeper slope and a higher xintercept than that of ER-negative tumours. The values for ER-unknown tumours were intermediate. A significant relationship of clonogenicity and hormone-induced proliferative response existed only for ER-negative and ER-unknown tumours. For ER-positive tumours, the relative increment in colony-formation in the presence of hormones was related inversely to the clonogenicity and was of independent prognostic significance. This increased proliferative response to hormones of low-clonogenic tumours could therefore be used as a criterion to select out the ER-positive proportion of tumours among ER-unknown tumours. Whatever the oestrogen-receptor status of the tumours, however, hormones increased the proliferative activity of the low-clonogenic tumours to a higher degree than that of the high-clonogenic tumours.
We defined the assay's worth for estimating the hormonal dependence of breast tumours by comparing the outcome of the assay with the clinical response of patients to endocrine treatments. Thirty-two patients received endocrine treatment just after the test. In the 15 patients with ER-positive tumours (listed in A, tumours of patients who achieved a complete or partial remission; *, tumours of patients who achieved less than a partial remission. The shift of distribution of HPR for responders and non-responders among patients with ER-positive tumours was significant (P=0.02, two-tailed Wilcoxon rank sum test). However, HPR alone could not significantly separate responders from failures in patients with ER-unknown tumours (P=0.09, two-tailed Wilcoxon rank sum test); nor could clonogenicity alone discriminate these two group (P=0.46). The discriminant analysis using both criteria is shown in Table III. seven patients that subsequently responded to endocrin treatment and five of eight patients that failed to respon (Figure 4a ). The shift of distribution of HPR for responder and failures was significnt at the P=0.02 level (two-taile Wilcoxon rank sum test).
In 17 patients the ER status was not known. The charac teristics of these patients with non-biopsiable tumours ar listed in Table II , and their responses to endocrine treal ments were analysed in terms both of clonogenicity and c hormone-induced proliferative response (HPR) (Figure 4b ). As can be seen, neither the shift of distribution of clonogenicity nor of HPR alone could significantly separate responders and non-responders to endocrine treatment among this group of patients with ER-unknown disease. The P values were 0.46 and 0.09, respectively (two-tailed Wilcoxon rank sum test). However, since hormone-dependent tumours were less clonogenic, the separation became more precise if the criterion for hormonal dependence of a 1.8-fold or greater increase in hormone-induced proliferative activity was restricted to tumours that formed less than 150 colonies. The combined criteria allowed 88% of patients to be correctly classified. A discriminant analysis for the combined criteria was performed (Table III) and yielded the following function: y = -20 + 0.43 ln HPR-0.0043 x number of colonies (y>0 for responders and y<0 for failures). The same analysis was also performed for ER-positive and ERunknown tumours combined, and the results are shown in Table III .
No retrospective correlations of in vitro and in vivo hormonal responsiveness of ER-negative tumours were obtained, because the predictive value of a negative ERassay result is close to 90% and patients with a negative test rarely receive endocrine treatments. Thus, we are not certain what the clinical meaning of the hormone-induced proliferative response of ER-negative tumours means. It is possible that our measures reflect growth-stimulation mediated by epidermal growth factor.
Discussion
We have previously reported that the in vitro response of breast tumours to growth-stimulatory hormones provided an estimate of the in vivo response to growth-inhibitory hormones. The present paper is concerned with predictors of response of ER-unknown tumours, e.g. patients with nonbiopsiable tumours. We found that clonogenicity of tumours was a determinant of hormonal dependence of tumours: lowclonogenic tumors tended to be hormone-dependent and high-clonogenic tumours tended to be hormone-independent. Clonogenicity was, in fact, a more powerful predictor of hormonal dependence of tumours than was the oestrogen receptor status of tumours. As illustrated by the hormoneinduced proliferative response versus clonogenicity curves, the s differences in slopes of ER-positive and ER-negative tumours reflected a higher degree of endocrine dependence of ER-positive tumours. However, the magnitude of the effect was relatively small, and the absence of this information did not jeopardise the discriminatory power of clonogenicity, as can be seen from our analysis of ERunknown tumours.
Conversely the proliferative response to hormones of lowclonogenic tumours was significantly higher for ER-positive tumours than for all others and there was no inverse One interpretation of these observations is that highclonogenic tumours have acquired growth autonomy, whereas low-clonogenic tumours remain under the control of external growth factors, and that the development of hormonal independence might be an evolutionary phenomenon. Correlations between clonogenicity of tumours and impaired survival of patients are in fact generally positive, and a shared ability of cells to survive the toxicity of concentrated agar and to kill the host may exist. Hence, it is possible that clonogenicity, like oestrogen receptors, is more closely related to differentiation than to oestrogen-dependence of tumours (clonogenicity being a measure of dedifferentiation and oestrogen receptors a measure of differentiation), and that the goodness of the test will ultimately depend on the relative completeness of the in vitro exposure to hormones and factors that regulate growth and differentiation of the mammary gland and/or of breast tumours in vivo.
In summary, our findings indicate that clonogenicity of tumours and the proliferative response of clonogenic cells to hormones together may provide measures of the hormonal dependence of breast tumours. Hormone-induced proliferative response of clonogenic cells could identify the responders among patients with ER-positive tumours; and proliferative response in conjunction with clonogenicity could substitute for the ER-assay in patients with nonbiopsiable tumours. Certainly, this hypothesis is datagenerated and should be verified in an independent sample of ER-unknown tumours.
The need for a test that supplements the oestrogen receptor assay is high. The efficacy of antitumour treatment depends on its inherent potential as well as on its proper application. Proper application is most important if treatment is used for cure and its effect cannot be measured. Proper allocation of available treatments could increase the cure rate of patients with early breast carcinoma by 35%, if the hormonal dependence of all (and not just half) the tumours could be assessed and if the hormonal dependence could be estimated with a test that provides a predictive value positive of 90% (and not just 50%). Thus, emphasis on developing more powerful predictive tests seems justified and necessary for the effective modulation of the disease course.
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